Search
15th Annual Sickle Cell and Thalassemia & 1st EHA European Sickle Cell Conference
October 26-31, 2020 | Virtual Global Conference
Steering Committee: B Andemariam, A Campbell, M Cappellini, S Chakravorty, R Colombatti, B Inusa, R Kesse-Adu, D Rees, A Taher, M Treadwell
In the last week of October, consultants and specialist psychologists, nurses, scientists and…
The root of evil: pre-leukemic clones that survive chemotherapy are linked to a higher risk of leukemia recurrence
Acute myeloid leukemia (AML) is an aggressive form of blood cancer. Treatment with intensive chemotherapy often leads to a period of freedom from overt disease called a remission. However, recurrence of the disease is common.
Read moreEHA mapping of adolescent and young adult (AYA) hematology patient care
EHA has launched a major consultation to understand patient care for Adolescents and Young Adults (AYA) with hematological diagnoses across Europe.
Read moreGenetic Predisposition to Blood Cancer (Rare diseases)
The objectives of the group are:
Share and extend clinical knowledge on the diagnosis and treatment of hematologic malignancies with germline predisposition.
EHA-AHA Tutorial on Biology and Management of Myeloid Malignancies
In collaboration with the Armenian Hematology Association. Dates: October 20-21, 2017
Location: Yerevan, Armenia
Chairs: S Daghbashyan, JJ Kiladjian & P Fenaux
Language: English (with simultaneous translation to Russian)
Online registration is closed.
100,000 Patient data sets: The value of data sharing to accelerate blood cancer research.
With almost 100,000 patient data sets identified and 63,000 already transferred to the HARMONY Big Data Platform, the HARMONY Alliance is fully equipped to facilitate state-of-the-art research into blood cancers.
Read moreWide Consensus Reached at Irish Presidency Conference on ‘Innovation and Patient Access to Personalised Medicine'
DUBLIN, March 25: Wide consensus emerged at the Irish Presidency Conference on ‘Innovation and Patient Access to Personalised Medicine’ on the need for radical change if Europe's approach to healthcare is to benefit from the potential of personalised medicine.
Read morePosition of EHA on Access to Medicines
There are many factors that compromise patient access to medicine. First and foremost, for a drug to be available, one has to be developed.
Major Conference: innovation and patient access to personalised medicine
The meeting will bring together researchers, patients, physicians, regulators and politicians, to explore the current barriers and how they can be dismantled.
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- 143
- 144
- 145
- 146
- 147
- 148
- 149
- 150
- 151
- 152
- 153
- 154
- 155
- 156
- 157
- 158
- 159
- 160
- 161
- 162
- 163
- 164
- 165
- 166
- 167
- 168
- 169
- 170
- 171
- 172
- »